Intellipharmaceutics International Inc. financial data

Symbol
IPCIF on OTC
Industry
Pharmaceutical Preparations
Location
30 Worcester Road, Toronto, Ontario, Canada
State of incorporation
Ontario, Canada
Fiscal year end
November 30
Latest financial report
20-F/A - Q4 2022 - Feb 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -115 % +19.8%
Return On Equity 26.9 % -37%
Return On Assets -201 % +7.58%
Operating Margin -147 % -100%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.1M shares
Common Stock, Shares, Outstanding 33.1M shares
Common Stock, Value, Issued 49.2M USD 0%
Weighted Average Number of Shares Outstanding, Basic 33.1M shares +39.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 789K USD
Cost of Revenue 17.4K USD
Research and Development Expense 2.4M USD -20.9%
Operating Income (Loss) -2.58M USD +31.9%
Net Income (Loss) Attributable to Parent -3.18M USD +19.9%
Earnings Per Share, Basic -0.03 USD/shares +25%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 69.5K USD -67.1%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Assets, Current 862K USD +55.3%
Property, Plant and Equipment, Net 666K USD -20.7%
Operating Lease, Right-of-Use Asset 37.8K USD -11.1%
Assets 1.57M USD +8.96%
Accounts Payable, Current 3.86M USD -9.39%
Employee-related Liabilities, Current 3.73M USD +31%
Accrued Liabilities, Current 3.52M USD
Liabilities, Current 14.4M USD
Operating Lease, Liability, Noncurrent 123K USD
Liabilities 12.5M USD +14.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 284K USD 0%
Retained Earnings (Accumulated Deficit) -107M USD -3.04%
Stockholders' Equity Attributable to Parent -12.9M USD -26.8%
Liabilities and Equity 1.57M USD +8.96%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 120K USD
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares, Issued 33.1M shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -293K USD +78.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 400K USD +402%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 27.4M USD +2.6%
Deferred Tax Assets, Gross 27.7M USD +2.53%
Operating Lease, Liability 43.1K USD -0.78%
Depreciation 40.6K USD -21.1%
Payments to Acquire Property, Plant, and Equipment 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -1.89M USD -538%
Property, Plant and Equipment, Gross 7.46M USD 0%
Operating Lease, Liability, Current 43.1K USD -0.78%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 820 USD
Deferred Tax Assets, Operating Loss Carryforwards 16.6M USD +1.45%
Operating Lease, Payments 87.3K USD
Additional Paid in Capital 45.1M USD +1.01%
Share-based Payment Arrangement, Expense 0 USD -100%
Interest Expense 234K USD -42.7%